反応式
[Mg:1].[CH3:2][C@@H:3]1[C@@H:17]2[C:12](=[C:13]([OH:32])[C@:14]3([OH:31])[C:22](=[O:23])[C:21]([C:24]([NH2:26])=[O:25])=[C:20]([OH:27])[C@@H:19]([N:28]([CH3:30])[CH3:29])[C@@H:15]3[C@H:16]2[OH:18])[C:10](=[O:11])[C:9]2[C:8]([OH:33])=[CH:7][CH:6]=[CH:5][C:4]1=2>>[Mg:1].[CH3:2][C@@H:3]1[C@@H:17]2[C:12](=[C:13]([OH:32])[C@:14]3([OH:31])[C:22](=[O:23])[C:21]([C:24]([NH2:26])=[O:25])=[C:20]([OH:27])[C@@H:19]([N:28]([CH3:29])[CH3:30])[C@@H:15]3[C@H:16]2[OH:18])[C:10](=[O:11])[C:9]2[C:8]([OH:33])=[CH:7][CH:6]=[CH:5][C:4]1=2参加物
3
実験手順
Magnesium ions combine with doxycycline in solution to form magnesium-doxycycline chelates. Magnesium oxide is a convenient and preferred source of magnesium ions, but other magnesium compounds useful for the purpose of this invention include magnesium chloride, magnesium acetate and magnesium sulfate. The molar ratio of magnesium to doxycycline in these compositions is preferably about from 1.8 to 2.2.
出典と根拠
- ORDレコード
- ord-3213ced261974d08a0bff12b113dc83f
- 出典データセット
- uspto-grants-1978_11
- 特許番号
- US04126680
関連ノート
読み込み中…